rx price color strategi
lot detail futur improv long wait ahead ep growth
spent signific amount time today confer call address issu
neg impact quarter outlook unfortun sum call laid
essenti flat ep growth although manag believ
grow core ebit signific headwind remain relat reimburs
lower brand inflat less gener deflat clarifi mechan
gener spot deflat moder manufactur level high singl digit
low singl digit base data put elev pressur wba gener
cog compani awp-bas reimburs gener dispens remain
fix creat modest margin squeez gener part guidanc
cut seem investor extrapol notion mail-ord pbm well
receiv gener mail reimburs primarili awp-bas contract
perhap part reason behind sell-off manag care stock
notabl mail-ord pbm busi ci howev ad
pluse minus call believ collect read-through
net posit net neg pbms/mco contrast read-through
probabl posit peer retail rx oper
detail futur plan manag indic spend bln next three
year move along partnership digit part evolut need
busi remain seen lead profit growth
compani also rais amount store expect close
follow today result lower ep ep
shift valuat basi reduc pt
base lower price-to-earnings prior calendar ep
lower price-to-earnings reflect ep growth next coupl year combin addit
industri risk relat hh drug propos maintain ew rate
page color outlook
quarterli annual ep usd
lower usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight walgreen continu move
reinvent busi reimburs
continu headwind compani cost
cut strategi much
reflect stock valuat
upsid case see sign improv
reimburs better traction
compani partnership lead multipl
pressur minim improv compani
oper structur lead multipl contract
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
walgreen transform program outlook
compani essenti see flat ep growth manag
pivot focu beyond transform program expect gener
annual save excess bln beyond compani continu
expect increas contribut partnership specif partnership compani
call labcorp
regard digit effort compani expect reduc cash spend
mln cost split evenli oper capit expenditur howev
save continu reinvest busi manag
quantifi bln next three year mln year within
oper expens within mln alloc toward partnership
digit
regard long-term outlook compani factor bln share
repurchas year estim contribut roughli ep growth
expect core grow rang note lt ep growth rang
appar compani alreadi guid flat ep growth
addit compani expect tax rate increas next
year eventu top compar tax rate
expect
addit color rx reimburs pressur
regard worse-than-expect rx reimburs pressur manag note
normal run-rat reimburs pressur
per quarter full annual
reimburs pressur howev came skew larg
portion reimburs headwind toward first half fep contract
bp headwind margin y/i impact gross margin
expect level remaind year
 growth /- tax ep ep ep bln worth share bln worth share bln worth share mln mln ep growth ep growth reposexclud anti-dilutiveexclud anti-dilut busi grow ex invest busi grow ex bp headwind bp headwind investmentsmargin contribut margin contribut barclay
 quarterli retail drugstor data pharmacyactualactualactualactualactualactualprojectedprojectedu drugstor datastor beg number number per chang yr/yrtot per dataprescript sale usa per scriptrev per prescript rx chang yr/yrpharmaci rx store sale data pharmaci front-end drugstor barclay
 quarterli incom statement addback invest affili incom revenu excl expens net rate rate excl non-controlling interest swiss net check ep fulli dilut share growth comparisontot incom expens net net per barclay
 annual retail drugstor data pharmacyactualactualactualprojectedprojectedprojectedprojectedu drugstor datastor beg number number per chang yr/yrtot per dataprescript sale usa per scriptrev per prescript rx chang yr/yrpharmaci rx store sale data pharmaci front-end drugstor barclay
 annual incom statement addback invest affili incom revenu excl expens net rate rate excl non-controlling interest swiss net check ep fulli dilut share growth comparisontot incom expens net net per barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
